We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Lab-on-a-Chip Technology Requires Standardization

By LabMedica International staff writers
Posted on 23 Aug 2012
Testing standards need to be developed and implemented before Lab-on-a-Chip (LOC) technology can be fully commercialized. More...


LOC devices are microchip-size systems, that can prepare and analyze tiny fluid samples with volumes ranging from a few microliters to sub-nanoliters, are envisioned to one day revolutionize how laboratory tasks such as diagnosing diseases are performed.

Physical scientists at the US National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) have suggested that standardized testing and measurement methods, will enable microelectromechanical systems (MEMS) LOC manufacturers at all stages of production, from processing of raw materials to final rollout of products, to accurately determine important physical characteristics of LOC devices such as dimensions, electrical surface properties, and fluid flow rates and temperatures.

To make the case for testing standards, the scientists have focused on autofluorescence, the background fluorescent glow of an LOC device that can interfere with the analysis of a sample. Multiple factors must be considered in the development of a testing standard for autofluorescence, including the materials used in the device, the measurement methods used to test the device, and how the measurements are interpreted. This material property of microfluidic and nanofluidic devices is of increasing importance due to the growing interest in sensitive fluorescence measurements performed in chips fabricated from plastics

Samuel M. Stavis, PhD, the author of the study, said: "Quality control during LOC device manufacturing may require different tests of autofluorescence throughout the process. There may be one measurement of autofluorescence from the block of plastic that is the base material for a chip, another once the block has been fashioned into the substrate in which the functional components are embedded, and yet another as the final device is completed. To manufacture lab on a chip devices with reliably low autofluorescence, accurate measurements may be needed at each stage."

Dr. Stavis emphasizes that it is important not to confuse testing standards with product standards, and to understand how the former facilitates the latter. He added, "A product standard specifies the technical requirements for a lab-on-a-chip device to be rated as top quality. A testing standard is needed to measure those specifications, as well as to make fair comparisons between competing products." The study was published on June 28, 2012, in the journal Lab on A Chip.

Related Links:

US National Institute of Standards and Technology



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.